CoChat
Sign Up
Cited by 122

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation

Frenzel, Christian, Teschke, Rolf·2016·International Journal of Molecular Sciences
DOI 10.3390/ijms17050588PMC PMC4881436
Open this paper in CoChat — free account

Abstract

Herb induced liver injury (HILI) and drug induced liver injury (DILI) share the common characteristic of chemical compounds as their causative agents, which were either produced by the plant or synthetic processes. Both, natural and synthetic chemicals are foreign products to the body and need metabolic degradation to be eliminated. During this process, hepatotoxic metabolites may be generated causing liver injury in susceptible patients. There is uncertainty, whether risk factors such as high lipophilicity or high daily and cumulative doses play a pathogenetic role for HILI, as these are under discussion for DILI. It is also often unclear, whether a HILI case has an idiosyncratic or an intrinsic background. Treatment with herbs of Western medicine or traditional Chinese medicine (TCM) rarely causes elevated liver tests (LT). However, HILI can develop to acute liver failure requiring liver transplantation in single cases. HILI is a diagnosis of exclusion, because clinical features of HILI are not specific as they are also found in many other liver diseases unrelated to herbal use. In strikingly increased liver tests signifying severe liver injury, herbal use has to be stopped. To establish HILI as the cause of liver damage, RUCAM (Roussel Uclaf Causality Assessment Method) is a useful tool. Diagnostic problems may emerge when alternative causes were not carefully excluded and the correct therapy is withheld. Future strategies should focus on RUCAM based causality assessment in suspected HILI cases and more regulatory efforts to provide all herbal medicines and herbal dietary supplements used as medicine with strict regulatory surveillance, considering them as herbal drugs and ascertaining an appropriate risk benefit balance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms17050588

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 8 references

Research works printed but not linked: 301

  1. Tu, 1999, The development of new antimalarial drugs: Qinghaosu and dihydro-qinghaosu, Chin. Med. J., 112, 976
  2. Efferth, 2008, The antiviral activities of artemisinin and artesunate, Clin. Infect. Dis., 47, 804, 10.1086/591195 · DOI · Paper page
  3. Maridass, 2008, Origin of plant derived medicines, Ethnobot Leaflets, 12, 373
  4. Pelkonen, 2014, Why is research on herbal medicinal products important and how can we improve quality?, J. Tradit. Complement. Med., 4, 1, 10.4103/2225-4110.124323 · DOI
  5. Teschke, 2015, Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders, World J. Gastroenterol., 21, 4466, 10.3748/wjg.v21.i15.4466 · DOI
  6. Teschke, 2015, Herbal hepatotoxicity in traditional and modern medicine: Actual key issues and new encouraging steps, Front. Pharmacol., 6, 72, 10.3389/fphar.2015.00072 · DOI · Paper page
  7. Calitz, 2015, Herbal hepatotoxicity: Current status, examples, and challenges, Expert Opin. Drug Metab. Toxicol., 11, 1551, 10.1517/17425255.2015.1064110 · DOI
  8. Zhao, P., Wang, C., Liu, W., Chen, G., Liu, X., Wang, X., Wang, B., Yu, L., Sun, Y., and Liang, X. (2013). Causes and outcomes of acute liver failure in China. PLoS ONE, 8. · DOI
  9. Avigan, 2016, Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States, Int. J. Mol. Sci., 17, 331, 10.3390/ijms17030331 · DOI
  10. Danan, 2016, RUCAM in drug and herb induced liver injury: The update, Int. J. Mol. Sci., 17, 14, 10.3390/ijms17010014 · DOI · Paper page
  11. Teschke, 2014, Green tea extract and the risk of drug-induced liver injury, Expert Opin. Drug Metab. Toxicol., 10, 1663, 10.1517/17425255.2014.971011 · DOI
  12. Zhang, 2012, Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: Current status and future perspective, J. Ethnopharmacol., 140, 519, 10.1016/j.jep.2012.01.058 · DOI
  13. Teschke, 2013, Clinical and causality assessment in herbal hepatotoxicity, Expert Opin. Drug Saf., 12, 339, 10.1517/14740338.2013.774371 · DOI
  14. Health Products and Food Branch Marketed Health Products Directorate Canadian Adverse Reaction Newsletter Editorial Team.. Available online: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v20n1-eng.php#a1t1.
  15. Ko, 1998, Adulterants in Asian patent medicines, N. Engl. J. Med., 339, 847, 10.1056/NEJM199809173391214 · DOI
  16. Huang, 1997, Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan, J. Clin. Pharmacol., 37, 344, 10.1002/j.1552-4604.1997.tb04312.x · DOI
  17. Espinoza, 1995, Arsenic and mercury in traditional Chinese herbal balls, N. Engl. J. Med., 333, 803, 10.1056/NEJM199509213331217 · DOI
  18. Gertner, 1995, Complications resulting from the use of Chinese herbal medications containing undeclared prescription drugs, Arthritis. Rheum., 38, 614, 10.1002/art.1780380506 · DOI
  19. Oransky, 1992, Chinese patent medicine as a potential source of mercury poisoning, Vet. Hum. Toxicol., 34, 235
  20. Navarro, 2013, Catechins in dietary supplements and hepatotoxicity, Dig. Dis. Sci., 58, 2682, 10.1007/s10620-013-2687-9 · DOI
  21. Mazzanti, 2009, Hepatotoxicity from green tea: A review of the literature and two unpublished cases, Eur. J. Clin. Pharmacol., 65, 331, 10.1007/s00228-008-0610-7 · DOI
  22. Sarma, 2008, Safety of green tea extract: A systematic review by the US Pharmacopeia, Drug Saf., 31, 469, 10.2165/00002018-200831060-00003 · DOI
  23. Wu, 2008, Clinical analysis of hepatic veno-occlusive disease induced by Sedum aizoon, Zhongguo Zhong Yao Za Zhi, 33, 2402
  24. Lin, 2011, Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum, J. Hepatol., 54, 666, 10.1016/j.jhep.2010.07.031 · DOI · Paper page
  25. Gao, 2006, Analysis of alkaloids in Sedum aizoon and establishment of hepatic veno-occlusive model in mice, Chin. J. Integr. Trad. Western Med. Dig., 14, 311
  26. Gao, 2012, Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids, J. Dig. Dis., 13, 33, 10.1111/j.1751-2980.2011.00552.x · DOI · Paper page
  27. Wang, 2014, Tusanqi and hepatic sinusoidal obstruction syndrome, J. Dig. Dis., 15, 105, 10.1111/1751-2980.12112 · DOI
  28. Teschke, 2012, Herbal hepatotoxicity: A tabular compilation of reported cases, Liver Int., 32, 1543, 10.1111/j.1478-3231.2012.02864.x · DOI
  29. Dai, 2006, Hepatic veno-occlusive disease induced by Gynura segetum: Report of two cases, Hepatobiliary Pancreat. Dis. Int., 5, 406
  30. Kumana, 1983, Hepatic veno-occlusive disease due to toxic alkaloid in herbal tea, Lancet, 322, 1360, 10.1016/S0140-6736(83)91112-1 · DOI
  31. Kumana, 1985, Herbal tea induced hepatic veno-occlusive disease: Quantification of toxic alkaloid exposure in adults, Gut, 26, 101, 10.1136/gut.26.1.101 · DOI
  32. Culvenor, 1986, Heliotropium lasiocarpum Fisch and Mey identified as cause of veno-occlusive disease due to herbal tea, Lancet, 1, 978, 10.1016/S0140-6736(86)91084-6 · DOI
  33. Ernst, 2002, Heavy metals in traditional Indian remedies, Eur. J. Clin. Pharmacol., 57, 891, 10.1007/s00228-001-0400-y · DOI
  34. Ernst, 2006, Review article. Methodological aspects of Traditional Chinese Medicine (TCM), Ann. Acad. Med. Singap., 35, 773, 10.47102/annals-acadmedsg.V35N11p773 · DOI
  35. Saper, 2008, Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the internet, JAMA, 300, 915, 10.1001/jama.300.8.915 · DOI · Paper page
  36. Bunchorntavakul, 2013, Review article: Herbal and dietary supplement hepatotoxicity, Aliment Pharmacol. Ther., 37, 3, 10.1111/apt.12109 · DOI · Paper page
  37. Dantuluri, 2011, Gotu Kola induced hepatotoxicity in a child—Need for causation with alternative remedies, Dig. Liver Dis., 43, 500, 10.1016/j.dld.2010.12.012 · DOI
  38. Jorge, 2005, Hepatotoxicity associated with the ingestion of Centella asiatica, Rev. Esp. Enferm. Dig., 97, 115, 10.4321/S1130-01082005000200006 · DOI
  39. Teschke, 2009, Severe hepatotoxicity by Indian Ayurvedic herbal products, A structured causality assessment, Ann. Hepatol., 8, 258, 10.1016/S1665-2681(19)31777-6 · DOI · Paper page
  40. Fleig, 1997, European multicenter study group. The ayurvedic drug Liv.52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double blind, placebo-controlled clinical trial, J. Hepatol., 126, 127
  41. Adachi, 2003, Hepatic injury in 12 patients taking the herbal loss aids Chaso and Onshido, Ann. Intern. Med., 139, 488, 10.7326/0003-4819-139-6-200309160-00012 · DOI
  42. Lau, 2004, A fatal case of hepatic failure possibly induced by nitrosofenfluramine: A case report, Med. Sci. Law, 44, 252, 10.1258/rsmmsl.44.3.252 · DOI
  43. Kanda, 2003, Severe hepatotoxicity associated with Chinese diet product “Ohnshidou-Genbi-Kounou”, J. Gastroenterol. Hepatol., 18, 354, 10.1046/j.1440-1746.2003.02952.x · DOI
  44. Kanda, 2003, N-nitroso-fenfluramine hepatotoxicity resembling chronic hepatitis, J. Gastroenterol. Hepatol., 18, 999, 10.1046/j.1440-1746.2003.03074.x · DOI
  45. Teschke, 2014, Traditional Chinese Medicine induced liver injury, J. Clin. Translat. Hepatol., 2, 80
  46. Teschke, 2015, Review Article: Mysterious Hawaii liver disease case—Naproxen overdose as cause rather than OxyELITE Pro?, J. Liver Clin. Res., 2, 1013
  47. Teschke, 2016, The mystery of the Hawaii liver disease cluster in summer 2013: A pragmatic and clinical approach to solve the problem, Ann. Hepatol., 15, 91, 10.5604/16652681.1184237 · DOI · Paper page
  48. Teschke, 2016, The Honolulu Liver disease cluster at the Medical Center: Its mysteries and challenges, Int. J. Mol. Sci., 17, 476, 10.3390/ijms17040476 · DOI · Paper page
  49. Ernst, 2002, Adulteration of Chinese herbal medicines with synthetic drugs: A systematic review, J. Int. Med., 252, 107, 10.1046/j.1365-2796.2002.00999.x · DOI
  50. Efferth, 2011, Toxicities by herbal medicines with emphasis to Traditional Chinese medicine, Curr. Drug Metab., 12, 989, 10.2174/138920011798062328 · DOI
  51. Shaw, 2010, Toxicological risks of Chinese herbs, Planta Med., 76, 2012, 10.1055/s-0030-1250533 · DOI
  52. Teschke, 2011, Kava and kava hepatotoxicity: Requirements for novel experimental, ethnobotanical, and clinical studies based on a review of the evidence, Phytother. Res., 25, 1262, 10.1002/ptr.3464 · DOI
  53. Rowe, 2012, Letter to the Editor: Are mould hepatotoxins responsible for kava hepatotoxicity?, Phytother. Res., 26, 1768, 10.1002/ptr.4620 · DOI
  54. Teschke, 2013, Contaminant hepatotoxins as culprits for kava hepatotoxicity—Fact or fiction?, Phytother. Res., 27, 472, 10.1002/ptr.4729 · DOI
  55. Teschke, 2011, Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits, Dig. Liver Dis., 43, 676, 10.1016/j.dld.2011.01.018 · DOI
  56. Lebot, 2006, The quality of kava consumed in the South Pacific, HerbalGram, 71, 34
  57. Schmidt, 2007, Quality criteria for kava, HerbalGram, 73, 45
  58. Teschke, 2011, Proposal for a Kava Quality Standardization Code, Food Chem. Toxicol., 49, 2503, 10.1016/j.fct.2011.06.075 · DOI
  59. Sarris, 2009, Editorial: Time for a reassessment of the use of kava in anxiety?, Complement. Ther. Med., 17, 121, 10.1016/j.ctim.2009.01.003 · DOI
  60. Sarris, 2011, Re-introduction of kava (Piper methysticum) to the EU: Is there a way forward?, Planta Med., 77, 107, 10.1055/s-0030-1250290 · DOI
  61. Sarris, 2009, Kava and St. John’s wort: Current evidence for use in mood and anxiety disorders, J. Altern. Complement. Med., 15, 827, 10.1089/acm.2009.0066 · DOI
  62. Sarris, 2009, The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum, Psychopharmacology, 205, 399, 10.1007/s00213-009-1549-9 · DOI
  63. Sarris, 2010, An explorative qualitative analysis of participants’ experience of using kava versus placebo in an RCT, Aust. J. Med. Herbalism., 22, 12
  64. Sarris, 2011, Kava: A comprehensive review of efficacy, safety, and psychopharmacology, Aust. N. Z. J. Psychiatry, 45, 36, 10.3109/00048674.2010.522554 · DOI
  65. Sarris, 2011, Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence, Eur. Neuropsychopharmacol., 21, 841, 10.1016/j.euroneuro.2011.04.002 · DOI
  66. Sarris, 2013, Kava in the treatment of generalized anxiety disorder: A double-blind, randomized, placebo-controlled study, J. Clin. Psychiatry, 33, 643
  67. Savage, 2015, Kava for the Treatment of Generalised Anxiety Disorder (K-GAD): Study protocol for a randomized controlled trial, Trials, 16, 493, 10.1186/s13063-015-0986-5 · DOI
  68. Ma, 2014, Chinese herbal medicine-induced liver injury, J. Clin. Transl. Hepatol., 2, 170
  69. Larrey, 2011, Herbal medicine hepatotoxicity: A new step with development of specific biomarkers, J. Hepatol., 54, 599, 10.1016/j.jhep.2010.12.003 · DOI
  70. Larrey, 1992, Hepatitis after germander (Teucrium chamaedrys) administration: Another instance of herbal medicine hepatotoxicity, Ann. Intern. Med., 117, 129, 10.7326/0003-4819-117-2-129 · DOI
  71. Urban, 2014, Genetic basis of drug-induced liver injury: Present and future, Semin. Liver Dis., 34, 123, 10.1055/s-0034-1375954 · DOI
  72. Andrade, 2009, Drug-induced liver injury: Insights from genetic studies, Pharmacogenomics, 10, 1467, 10.2217/pgs.09.111 · DOI
  73. Chen, 2013, High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
  74. Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI
  75. Zimmerman, H.J. (1999). Hepatotoxicity, Lippincott Williams & Wilkins.
  76. Teschke, 2012, Greater Celandine hepatotoxicity: A clinical review, Ann. Hepatol., 11, 838, 10.1016/S1665-2681(19)31408-5 · DOI
  77. Teschke, 2012, Suspected Greater Celandine hepatotoxicity: Liver specific causality evaluation of published case reports from Europe, Eur. J. Gastroenterol. Hepatol., 24, 270, 10.1097/MEG.0b013e32834f993f · DOI
  78. Teschke, 2010, Kava hepatotoxicity: A clinical review, Ann. Hepatol., 9, 251, 10.1016/S1665-2681(19)31634-5 · DOI
  79. Teschke, 2008, Kava hepatotoxicity: A clinical survey and critical analysis of 26 suspected cases, Eur. J. Gastroenterol. Hepatol., 20, 1182, 10.1097/MEG.0b013e3283036768 · DOI
  80. Teschke, 2003, Kava extracts: Safety and risks including rare hepatotoxicity, Phytomedicine, 10, 440, 10.1078/0944-7113-00314 · DOI
  81. Teschke, 2008, Kava hepatotoxicity: A European view, N. Z. Med. J., 121, 90
  82. Teschke, 2009, Kava hepatotoxicity: Regulatory data selection and causality assessment, Dig. Liver Dis., 41, 891, 10.1016/j.dld.2009.04.003 · DOI
  83. Teschke, 2010, Risk of kava hepatotoxicity and the FDA consumer advisory, J. Am. Med. Assoc., 304, 2174, 10.1001/jama.2010.1689 · DOI
  84. Teschke, 2010, Kava hepatotoxicity: Pathogenetic aspects and prospective considerations, Liver Int., 30, 1270, 10.1111/j.1478-3231.2010.02308.x · DOI
  85. Teschke, 2011, Special report. Kava and the risk of liver toxicity: Past, current, and future, Am. Herb. Prod. Assoc., 26, 1
  86. Teschke, 2011, Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate?, Regul. Toxicol. Pharmacol., 59, 1, 10.1016/j.yrtph.2010.09.006 · DOI
  87. Olsen, 2011, Constituents in kava extracts potentially involved in hepatotoxicity: A review, Chem. Res. Toxicol., 24, 992, 10.1021/tx100412m · DOI
  88. Martin, A.C., Johnston, E., Xing, C., and Hegeman, A.D. (2014). Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster). PLoS ONE, 9. · DOI
  89. Schmidt, 2014, German court ruling reverses kava ban; German regulatory authority appeals decision, HerbalGram, 103, 38
  90. Kuchta, 2015, German kava ban lifted by court: The alleged hepatotoxicity of kava (Piper methysticum) as a case of ill-defined herbal drug identity, lacking quality control, and misguided regulatory politics, Planta Med., 81, 1647, 10.1055/s-0035-1558295 · DOI
  91. Fu, 2004, Pyrrolizidine alkaloids—Genotoxicity, metabolism enzymes, metabolic activation, and mechanisms, Drug Metab. Rev., 36, 1, 10.1081/DMR-120028426 · DOI
  92. Roulet, 1988, Hepatic veno-occlusive disease in newborn infant of a woman drinking herbal tea, J. Pediatr., 112, 433, 10.1016/S0022-3476(88)80330-5 · DOI
  93. Lee, C.H., Wang, J.D., and Chen, P.C. (2011). Risk of liver injury associated with Chinese herbal products containing Radix bupleuri in 639,779 patients with hepatitis B virus infection. PLoS ONE, 6. · DOI
  94. Liu, 2014, Review on the toxic effects of radix Bupleuri, Curr. Opin. Complement. Altern. Med., 1, 3
  95. Lei, X., Chen, J., Ren, J., Li, Y., Zhai, J., Mu, W., Zhang, L., Zheng, W., Tian, G., and Shang, H. (2015). Liver damage associated with Polygonum multiflorum Thunb.: A systematic review of case reports and case series. Evid. Based Complement. Altern. Med. · DOI
  96. Mazzanti, 2015, Hepatotoxicity of green tea: An update, Arch. Toxicol., 89, 1175, 10.1007/s00204-015-1521-x · DOI · Paper page
  97. Chau, 2011, Causality assessment of herb-induced liver injury using multidisciplinary approach and the Roussel Uclaf Causality assessment Method (RUCAM), Clin. Toxicol., 49, 34, 10.3109/15563650.2010.537662 · DOI · Paper page
  98. Zhou, 2013, Biomarkers of drug-induced liver injury, Curr. Biomark. Find, 3, 1
  99. Yang, 2012, Current and emerging biomarkers of hepatotoxicity, Curr. Biomark. Find, 2, 43
  100. Mahady, 2008, United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity, Menopause, 15, 628, 10.1097/gme.0b013e31816054bf · DOI
  101. Teschke, 2009, Suspected black cohosh hepatotoxicity—Challenges and pitfalls of causality assessment, Maturitas, 63, 302, 10.1016/j.maturitas.2009.05.006 · DOI
  102. Teschke, 2010, Black cohosh and suspected hepatotoxicity—Inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: A critical review, Menopause, 17, 426, 10.1097/gme.0b013e3181c5159c · DOI
  103. Teschke, 2012, Suspected herbal hepatotoxicity: Requirements for appropriate causality assessment by the US Pharmacopeia, Drug Saf., 12, 1091, 10.1007/BF03261996 · DOI
  104. Teschke, 2011, Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: Is the liver unspecific Naranjo scale precise enough to ascertain causality?, Pharmacoepidemiol. Drug Saf., 20, 567, 10.1002/pds.2127 · DOI
  105. Teschke, 2011, Herb induced liver injury presumably caused by black cohosh: A survey of initially purported cases and herbal quality specifications, Ann. Hepatol., 11, 249, 10.1016/S1665-2681(19)31536-4 · DOI
  106. Liss, 2009, Drug-induced liver injury: What was new in 2008?, Expert Opin. Drug Metab. Toxicol., 5, 843, 10.1517/17425250903018904 · DOI
  107. Mills, M., and Bone, K. (2005). The Essential Guide to Herbal Safety, Elsevier Churchill Livingstone.
  108. Teschke, 2012, Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: Was causality adequately ascertained?, Regul. Toxicol. Pharmacol., 63, 1, 10.1016/j.yrtph.2012.02.009 · DOI
  109. Teschke, 2012, Suspected herbal hepatotoxicity: The pharmacovigilance dilemma with disputed and obsolete evaluation methods, Regul. Toxicol. Pharmacol., 64, 343, 10.1016/j.yrtph.2012.06.010 · DOI
  110. Teschke, 2012, Initially purported hepatotoxicity by Pelargonium sidoides: The dilemma of pharmacovigilance and proposals for improvements, Ann. Hepatol., 11, 500, 10.1016/S1665-2681(19)31464-4 · DOI
  111. Teschke, 2013, Herbalife hepatotoxicity: Evaluation of cases with positive reexposure tests, World J. Hepatol., 5, 353, 10.4254/wjh.v5.i7.353 · DOI
  112. Melchart, 1999, Liver enzyme elevations in patients treated with traditional Chinese medicine, JAMA, 282, 28, 10.1001/jama.282.1.28 · DOI
  113. Au, 2011, Review article: Drug induced liver injury—Its pathophysiology and evolving diagnostic tools, Aliment. Pharmacol. Ther., 34, 11, 10.1111/j.1365-2036.2011.04674.x · DOI
  114. Dalton, 2007, The role of hepatitis E virus testing in drug-induced liver injury, Aliment. Pharmacol. Ther., 26, 1429, 10.1111/j.1365-2036.2007.03504.x · DOI
  115. Davern, 2011, Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury, Gastroenterology, 141, 1665, 10.1053/j.gastro.2011.07.051 · DOI
  116. Hoofnagle, 2012, Review article: Hepatitis E, N. Engl. J. Med., 367, 1237, 10.1056/NEJMra1204512 · DOI
  117. Teschke, 2015, Editorial. Drug-induced liver injury: Expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment, Gastroenterology, 148, 1271, 10.1053/j.gastro.2015.04.027 · DOI
  118. Chen, 2012, Hepatitis E masquerading as drug–induced liver injury, Hepatology, 56, 2420, 10.1002/hep.26158 · DOI
  119. Danan, 1993, Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge, J. Clin. Epidemiol., 46, 1331, 10.1016/0895-4356(93)90102-7 · DOI · Paper page
  120. Teschke, 2015, Traditional Chinese Medicine and herbal hepatotoxicity: A tabular compilation of reported cases, Ann. Hepatol., 14, 7, 10.1016/S1665-2681(19)30796-3 · DOI · Paper page
  121. Teschke, 2014, Herbal hepatotoxicity: Analysis of cases with initially reported positive reexposure tests, Dig. Liver Dis., 46, 264, 10.1016/j.dld.2013.10.020 · DOI
  122. Naser, 2011, Hepatotoxicity suspected by black cohosh: No evidence by metaanalysis of randomized controlled clinical trials for isopropanolic black cohosh extract, Menopause, 18, 366, 10.1097/gme.0b013e3181fcb2a6 · DOI
  123. Teschke, 2013, Herbal hepatotoxicity: Suspected cases assessed for alternative causes, Eur. J. Gastroenterol. Hepatol., 25, 1093, 10.1097/MEG.0b013e3283603e89 · DOI
  124. Teschke, 2014, Drug induced liver injury: Accuracy of diagnosis in published reports, Ann. Hepatol., 13, 248, 10.1016/S1665-2681(19)30888-9 · DOI
  125. Teschke, 2011, Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): Causality assessment of 22 spontaneous reports, Regul. Toxicol. Pharmacol., 61, 282, 10.1016/j.yrtph.2011.08.008 · DOI
  126. Haller, 2002, Making a diagnosis of herbal-related toxic hepatitis, West J. Med., 176, 39, 10.1136/ewjm.176.1.39 · DOI
  127. Estes, 2003, High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure, Arch. Surg., 138, 852, 10.1001/archsurg.138.8.852 · DOI
  128. Murray, 1992, Toxicity of Chinese herbal remedies, Lancet, 340, 674
  129. Kane, 1995, Hepatitis induced by traditional Chinese herbs: Possible toxic components, Gut, 36, 146, 10.1136/gut.36.1.146 · DOI
  130. Vautier, 1995, Safety of complementary medicines should be monitored, BMJ, 311, 633, 10.1136/bmj.311.7005.633b · DOI
  131. Yuen, 2006, Traditional Chinese Medicine causing hepatotoxicity in patients with chronic hepatitis B infection: A 1-year prospective study, Aliment. Pharmacol. Ther., 24, 1179, 10.1111/j.1365-2036.2006.03111.x · DOI · Paper page
  132. Kang, 2008, Clinical characteristics of 159 cases of acute toxic hepatitis, Korean J. Hepatol., 14, 483, 10.3350/kjhep.2008.14.4.483 · DOI · Paper page
  133. Sohn, 2008, Liver transplantation for acute toxic hepatitis due to herbal medicines and preparations, J. Korean Soc. Clin. Toxicol., 6, 110
  134. Cortez, E., Boulger, C., and Bernard, A. (2012). Ban Tu Wan hepatotoxicity. BMJ Case Rep. · DOI
  135. Sangsuwan, 2004, Randomized controlled trial of Tinospora crispa for additional therapy in patients with type 2 diabetes mellitus, J. Med. Assoc. Thai., 87, 543
  136. Motoyama, 2008, Drug-induced liver injury caused by a herbal medicine, bofu-tsu-sho-san, Nihon Shokakibyo Gakkai Zasshi, 105, 1234
  137. Hwang, 2001, Case of acute cholestatic hepatitis caused by the seeds of Psoralea-corylifolia, Korean J. Hepatol., 7, 341
  138. Nam, 2005, A case of acute cholestatic hepatitis associated with the seeds of Psoralea corylifolia (Boh-Gol-Zhee), Clin. Toxicol., 43, 589, 10.1081/CLT-200068863 · DOI
  139. Cheung, 2009, Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related propriety medicine, Clin. Toxicol., 47, 683, 10.1080/15563650903059136 · DOI · Paper page
  140. Chau, 2008, Drug-induced liver injury: An update, Hong Kong Med. Diary, 13, 23
  141. Lin, 2002, Hepatotoxicity caused by Breynia officinalis, Vet. Hum. Toxicol., 44, 87
  142. Lin, 2003, Acute poisonings with Breynia officinalis—An outbreak of hepatotoxicity, J. Toxicol. Clin. Toxicol., 41, 591, 10.1081/CLT-120023760 · DOI
  143. Yoshida, 1996, Chinese herbal medicine, fulminant hepatitis, and liver transplantation, Am. J. Gastroenterol., 91, 2647
  144. Kamiyama, 1997, Autoimmune hepatitis triggered by administration of an herbal medicine, Am. J. Gastroenterol., 92, 703
  145. Verucchi, 2002, Acute hepatitis induced by traditional Chinese herbs used in the treatment of psoriasis, J. Gastroenterol. Hepatol., 17, 1342, 10.1046/j.1440-1746.2002.02887.x · DOI
  146. Kim, 2009, Two cases of toxic hepatitis caused by arrowroot juice, Korean J. Hepatol., 15, 504, 10.3350/kjhep.2009.15.4.504 · DOI · Paper page
  147. Bae, 2010, Toxic hepatitis associated with Polygoni multiflori, Korean J. Hepatol., 16, 182, 10.3350/kjhep.2010.16.2.182 · DOI · Paper page
  148. Gono, 2010, Clinical analysis of cases with drug-induced liver injury for Kampo medicine, Kampo Med., 61, 828, 10.3937/kampomed.61.828 · DOI
  149. Linnebur, 2010, Hepatotoxicity associated with Chinese skullcap contained in Move Free Advanced dietary supplement: Two case reports and review of the literature, Pharmacotherapy, 750, 258e
  150. Yang, 2012, Herbal hepatotoxicity from Chinese skullcap: A case report, World J. Hepatol., 4, 231, 10.4254/wjh.v4.i7.231 · DOI
  151. Dhanasekaran, R., Owens, V., and Sanchez, W. (2013). Chinese skullcap in Move Free arthritis supplement causes drug induced liver injury and pulmonary infiltrates. Case Rep. Hepatol. · DOI
  152. Kang, 2009, A case of acute cholestatic hepatitis induced by Corydalis speciosa Max, Korean J. Hepatol., 15, 517, 10.3350/kjhep.2009.15.4.517 · DOI · Paper page
  153. Kim, 2012, A pediatric case of toxic hepatitis induced by Hovenia dulcis, Pediatr. Gastroenterol. Hepatol. Nutr., 15, 111, 10.5223/pghn.2012.15.2.111 · DOI · Paper page
  154. Woolf, 1994, Acute hepatitis associated with the Chinese herbal product Jin Bu Huan, Ann. Intern. Med., 121, 729, 10.7326/0003-4819-121-10-199411150-00001 · DOI
  155. Horowitz, 1996, The clinical spectrum of Jin Bu Huan toxicity, Arch Intern. Med., 156, 899, 10.1001/archinte.1996.00440080101012 · DOI
  156. Picciotti, 1998, Chronic hepatitis induced by Jin Bu Huan, J. Hepatol., 28, 165, 10.1016/S0168-8278(98)80217-1 · DOI
  157. Divinsky, 2002, Case report: Jin Bu Huan—Not so benign herbal medicine, Can Fam. Phys., 48, 1640
  158. Inoue, 2011, Liver injury induced by the Japanese herbal drug kamishoyosan, Gastroenterol. Hepatol., 7, 692
  159. Gento, 2004, Acute hepatitis associated with Camellia tea and Orthosiphon stamineus ingestion, Gastroenterol. Hepatol., 27, 559, 10.1016/S0210-5705(03)70527-5 · DOI
  160. Petitpain, 2004, Probable hepatotoxicity from epigallocatecol gallate used for Phytotherapy, Gastroenterol. Clin. Biol., 28, 404, 10.1016/S0399-8320(04)94944-5 · DOI
  161. Gloro, 2005, Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea, Eur. J. Gastroenterol. Hepatol., 17, 1135, 10.1097/00042737-200510000-00021 · DOI
  162. Bonkovsky, 2006, Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis), Ann. Intern. Med., 144, 68, 10.7326/0003-4819-144-1-200601030-00020 · DOI
  163. Molinari, 2006, Acute liver failure induced by green tea extracts: Case reports and review of the literature, Liver Transpl., 12, 1892, 10.1002/lt.21021 · DOI
  164. Olsson, 2007, Serious adverse liver reactions associated with herbal weight loss supplements, J. Hepatol., 47, 295, 10.1016/j.jhep.2007.05.010 · DOI
  165. Borraz, 2008, Liver injury induced by “natural remedies”: An analysis of cases submitted to the Spanish Liver Toxicity Registry, Rev. Esp. Enferm. Dig., 100, 688
  166. Rohde, 2011, Toxic hepatitis triggered by green tea, Ugeskr Laeger, 173, 205
  167. Nadir, 1996, Acute hepatitis associated with the use of a Chinese herbal product, ma-huang, Am. J. Gastroenterol., 91, 1436
  168. Borum, 2001, Fulminant exacerbation of autoimmune hepatitis after the use of Ma Huang, Am. J. Gastroenterol., 96, 1654, 10.1111/j.1572-0241.2001.03827.x · DOI
  169. Skoulidis, 2005, Ma huang associated acute liver failure requiring liver transplantation, Eur. J. Gastroenterol. Hepatol., 17, 581, 10.1097/00042737-200505000-00017 · DOI
  170. Aiba, 2007, Liver injury induced by a Japanese herbal medicine, sairei-to (TJ-114, Bupleurum and Hoelen combination, Chai-Ling-Tang), J. Gastroenterol. Hepatol., 22, 762, 10.1111/j.1440-1746.2006.03373.x · DOI
  171. Tsuda, 2010, Discrepancy between clinical course and drug-induced lymphocyte stimulation tests in a case of saireito-induced liver injury accompanied by Sjögren syndrome, J. Altern. Complement. Med., 16, 501, 10.1089/acm.2009.0183 · DOI · Paper page
  172. Chen, 2007, Hepatic veno-occlusive disease associated with the use of Gynura segetum, Eur. J. Intern. Med., 18, 609, 10.1016/j.ejim.2007.03.006 · DOI
  173. Li, 2010, Sinusoidal obstruction syndrome associated with the ingestion of Gynura root, Clin. Toxicol., 48, 962, 10.3109/15563650.2010.527851 · DOI
  174. Restrepo, 2006, Acute hepatitis due to shen-min: A herbal product derived from Polygonum multiflorum, J. Clin. Gastroenterol., 40, 629, 10.1097/00004836-200608000-00014 · DOI
  175. But, 1996, Hepatitis related to the Chinese medicine Shou-wu-pian manufactured from Polygonum multiflorum, Vet. Hum. Toxicol., 38, 280
  176. Park, 2001, Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum, J. Gastroenterol. Hepatol., 16, 115, 10.1046/j.1440-1746.2001.02309.x · DOI
  177. Battinelli, 2004, New case of acute hepatitis following the consumption of Shou Wu Pian, a Chinese herbal product derived from Polygonum multiflorum, Ann. Intern. Med., 140, 587
  178. Panis, 2005, Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation, J. Pediat. Gastroenterol. Nutr., 41, 256, 10.1097/01.MPG.0000164699.41282.67 · DOI
  179. Laird, 2008, Acute hepatitis associated with the use of an herbal supplement (Polygonum multiflorum) mimicking iron-overload syndrome, Clin. Gastroenterol., 42, 861, 10.1097/MCG.0b013e3181492515 · DOI
  180. Furukawa, 2010, Toxic hepatitis induced by Show-Wu-Pian, a Chinese herbal preparation, Intern. Med., 49, 1537, 10.2169/internalmedicine.49.3509 · DOI
  181. Valente, 2010, Herbal hepatotoxicity: A case of difficult interpretation, Eur. Rev. Med. Pharmacol. Sci., 14, 865
  182. Jung, 2011, Drug-induced liver injury: Twenty five cases of acute hepatitis following ingestion of Polygonum multiflorum Thun, Gut Liver, 5, 493, 10.5009/gnl.2011.5.4.493 · DOI · Paper page
  183. Banarova, 2012, Toxic hepatitis induced by Polygonum multiflorum, Vnitr Lek, 58, 958
  184. Cohen, 2012, Hepatotoxicity associated with the use of White Flood, a nutritional supplement, Pract. Gastroenterol., 10, 45
  185. Itoh, 1995, Liver injuries induced by herbal medicine, Syo-saiko-to (xiao-chai-hu-tang), Dig. Dis. Sci., 40, 1845, 10.1007/BF02212712 · DOI · Paper page
  186. Hsu, 2006, Acute hepatitis induced by Chinese hepatoprotective herb xiao-chai-hu-tang, J. Chin. Med. Assoc., 69, 86, 10.1016/S1726-4901(09)70119-4 · DOI
  187. Rabe, 2005, Acute hepatitis induced by an aloe vera preparation: A case report, World J. Gastroenterol., 11, 303, 10.3748/wjg.v11.i2.303 · DOI
  188. Kanat, 2006, Aloe vera-induced acute toxic hepatitis in a healthy young man, Eur. J. Intern. Med., 17, 589, 10.1016/j.ejim.2006.04.017 · DOI
  189. Bottenberg, 2007, Oral Aloe vera-induced hepatitis, Ann. Pharmacother., 41, 1740, 10.1345/aph.1K132 · DOI
  190. Yang, 2010, Aloe-induced toxic hepatitis, J. Korean Med. Sci., 25, 492, 10.3346/jkms.2010.25.3.492 · DOI · Paper page
  191. Smith, 1981, Plant sources of hepatotoxic pyrrolizidine alkaloids, J. Nat. Prod., 44, 129, 10.1021/np50014a001 · DOI
  192. Nadir, 2000, Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: Case report and review of herbal hepatotoxicity, Am. J. Gastroenterol., 95, 3634, 10.1111/j.1572-0241.2000.03386.x · DOI
  193. Katz, 1990, Herbal hepatitis: Subacute hepatic necrosis secondary to chaparral leaf, J. Clin. Gastroenterol., 12, 203, 10.1097/00004836-199004000-00021 · DOI
  194. Centers of Disease Control and Prevention (1992). Chaparral-induced toxic hepatitis California and Texas 1992. J. Am. Med. Ass., 268, 3295–3298. · DOI
  195. Smith, 1993, Acute hepatitis induced by the ingestion of the herbal medication chaparral, Aust. N. Z. J. Med., 23, 526, 10.1111/j.1445-5994.1993.tb01846.x · DOI
  196. Alderman, 1994, Cholestatic hepatitis after ingestion of chaparral leaf: Confirmation by endoscopic retrograde cholangio-pancreatography and liver biopsy, J. Clin. Gastroenterol., 19, 242, 10.1097/00004836-199410000-00016 · DOI
  197. Batchelor, 1995, Chaparral-induced hepatic injury, Am. J. Gastroenterol., 90, 831
  198. Gordon, 1995, Chaparral ingestion: The broadening spectrum of liver injury caused by herbal medications, J. Am. Med. Assoc., 273, 489, 10.1001/jama.1995.03520300063038 · DOI
  199. Sheikh, 1997, Chaparral-associated hepatotoxicity, Arch. Intern. Med., 157, 913, 10.1001/archinte.1997.00440290099011 · DOI
  200. Ridker, 1985, Hepatic venoocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements, Gastroenterology, 88, 1050, 10.1016/S0016-5085(85)80027-5 · DOI

200 of 301 shown

Cited by

Sorted by citations

See all 122

Metadata

Authors
Frenzel, C., & Teschke, R.
Affiliations
  • Department of Medicine I, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany
  • Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/Main, 63450 Hanau, Germany
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2016-04-27
Volume
17
Issue
5
Pages
588
ISSN
1422-0067
DOI
10.3390/ijms17050588
PMC
PMC4881436
Cited by
122
References
8
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review